VERACYTE, INC.(VCYT)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
VERACYTE, INC. (VCYT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VCYT at 68.6/100 on a 32-signal composite quality model, placing it at rank #312 of 2,960 stocks — the top 25% of the AI-ranked universe. VCYT scores in the top quartile across profitability (84.4), free cash flow (83.6), balance sheet strength (81.0). Areas of concern include institutional flow (33.1) and revenue scale (38.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), VERACYTE, INC. reports quarterly revenue of $150.3M, net income of $25.5M, an operating margin of 15.3%. Top institutional holders of VCYT by reported 13-F value include BlackRock, FMR, Artisan Partners Limited Partnership, based on the most recent SEC filings. VCYT trades on the Nasdaq exchange and files with the SEC under CIK 1384101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VCYT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VERACYTE, INC. directly from SEC EDGAR.
AI Quality Score
68.6/100
AI Rank
#312
Revenue
$150.3M
Net Income
$25.5M
Free Cash Flow
$43.0M
Operating Margin
15.3%
VCYT key financials by period
VERACYTE, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$517.1M
$66.4M
11.2%
FY 2024
10-K
$445.8M
$24.1M
3.6%
FY 2023
10-K
$361.1M
$-74.4M
-23.8%
FY 2022
10-K
$296.5M
$-36.6M
-13.9%
FY 2021
10-K
$219.5M
$-75.6M
-37.3%
FY 2020
10-K
$117.5M
$-34.9M
-30.1%
Institutions holding VCYT
Institutional investors reporting a position in VERACYTE, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Veracyte grew Q2 FY2026 revenue 15% YoY to $150.3M on 19% testing revenue growth and swung to $23.0M operating income from a $5.3M operating loss a year earlier.
Biggest Revenue Drivers
Testing revenue$145.7M+19% YoY
Driven by a 14% volume increase, improved ASP, and prior period collections
Product revenue$3.9M+7% YoY
Primarily international sales of the Prosigna breast cancer IVD kit
Biggest Revenue Drivers
Total revenue: $150.3M+15% YoY
Testing revenue$145.7M+19% YoY
Driven by a 14% volume increase, improved ASP, and prior period collections
Product revenue$3.9M+7% YoY
Primarily international sales of the Prosigna breast cancer IVD kit
Biopharmaceutical and other revenue$0.8M-81% YoY
Discontinuation of biopharmaceutical, contract manufacturing and development services previously conducted in France following Veracyte SAS restructuring
Largest Expense Items
Cost of testing revenue$36.3M+12% YoY
Increased testing volume, higher staffing for volume and new test launches, and infrastructure buildout, partly offset by lab efficiencies
Research and development$29.4M+81% YoY
$6.5M shift of software development expenses from G&A now fully dedicated to product development, plus added headcount and merit increases
Selling and marketing$28.3M+12% YoY
Annual compensation increases, headcount additions, and tradeshow/new test launch costs
General and administrative$27.4M-15% YoY
Reassignment of software development costs to R&D and customer service costs to cost of revenue, plus lower legal, audit and tax fees
Margins: Gross profit rose 21% YoY to $108.5M as cost of revenue grew just 3% versus 15% revenue growth. Operating income reached $23.0M versus a $5.3M loss a year earlier, aided by the absence of the prior year's $20.5M non-cash impairment charge.
Watch Items from the Filing
Medicare and UnitedHealthcare together represented 46% of total revenue in Q2 2026 (33% and 13%, respectively), a significant payer concentration.
Veracyte's patent infringement suit against Sonic Healthcare USA over ThyroSeq v3 cleared a motion to dismiss, but the USPTO granted an ex parte reexamination of one asserted patent on July 21, 2026; jury trial set for Q1 next year.
R&D expense grew 81% YoY as spending shifted toward TrueMRD platform development and new IVD products, a step-up in investment ahead of any related revenue.
Cash, cash equivalents and short-term investments rose to $485.2M, up $72.3M in the first half of 2026, supported by $81.0M of operating cash flow.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
